MedPath

Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery

Not Applicable
Completed
Conditions
Flow-mediated Dilation Evaluation of the Brachial Artery
Interventions
Drug: Placebo
Registration Number
NCT01679795
Lead Sponsor
Federal University of Minas Gerais
Brief Summary

The aim of this study is to evaluate the vascular effects of tibolone on climateric women measured by flow-mediated evaluation of the brachial artery using high resolution ultrasound and compare to placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Women without menstrual cycles whithin the last 12 months and FSH>30IU/L
  • Healthy women
  • Women that were not using drugs with potential vascular effect whithin the last 1 year
  • Women that never used hormone replacement therapy
Exclusion Criteria
  • Smoking
  • Blood Pressure > 160/90 mm Hg.
  • Breast and or endometrial cancer
  • History of acute myocardial infarction
  • Diabetes
  • Vaginal bleeding of any origin
  • Hepatic disease
  • thrombophlebitis or thromboembolic disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo usePlaceboPatients will use placebo for 30 days
TiboloneTibolonepatientes will use tibolone 2,5mg/day during 30 days
Primary Outcome Measures
NameTimeMethod
Flow-mediated dilation of the brachial artery one month after treatment started Flow-mediated dilation of the brachial artery one month after treatment started Flow-mediated dilation of the brachial artery30 days

Flow-mediated dilation will be measured by high resolution ultrasound

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

hospital das Clinicas - Universidade Federal de Minas Gerais

🇧🇷

belo Horizonte, minas Gerais, Brazil

© Copyright 2025. All Rights Reserved by MedPath